The stock was first identified by Tony Locantro about 24 months ago as having some good fundamentals.
It was priced at about 35 cents. This was obviously well before the biotech run the market had seen over the last 12 months.
During that time ADAlta has continued to go about its business relatively unnoticed by the market until raising capital 3-4 months ago.
This was done at a price of 15 cents which is half the stock price was 2 years ago.
when the CEO left many sold. Tony's recommendation remain unchanged as a buy.
The board of ADAlta are well credentialed. The work pipeline and quality of their work is probably the most important aspects of the company to focus on.
Adalta has recently signed off with GE healthcare. The other company to recently partner with GE healthcare is EMV.
EMV has some links to nanosonics which had performed exceptionally well.
As such we see that GE only seem to want to partner with biotechs of the best quality.
Many would be put off by the chart.
When end you go through the presentation you think this could easily be a $100 mill cap business.
At 15 cents it's a $23 mill cap. As such the greatest risk would appear to be not holding a few.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)